裸体抗体和抗体-药物合物:针对儿童急性淋巴细胞白血病的向治疗
Erica Brivio1, Francisco Bautista1, C Michel Zwaan2
1Princess Máxima Center for Pediatric Oncology, Utrecht.
Haematologica
|June 4, 2024
概括
新型免疫疗法和向抗体正在改变儿童急性淋巴细胞白血病 (ALL) 治疗. 这些进展旨在提高儿童ALL患者的治愈率和减少化疗毒性.
科学领域:
- 儿科血液学 瘤学 儿科血液学
- 癌症免疫疗法癌症免疫疗法
- 白血病研究研究 白血病研究
背景情况:
- 儿童急性淋巴细胞白血病 (ALL) 存活率超过90%,但治疗所有患者和减少治疗毒性仍然存在挑战.
- 新型免疫疗法和向抗体正在成为ALL治疗的重大进展.
- 目前的研究重点是取代有毒化疗,同时保持高治愈率.
研究的目的:
- 审查新型免疫疗法和向抗体对儿科ALL治疗模式的影响.
- 为了突出特定药物的作用,如blinatumomab,inotuzumab,ozogamicin和daratumumab在ALL治疗中的作用.
- 讨论成人ALL治疗创新的潜在转化到儿科护理.
主要方法:
- 关于儿科ALL治疗的最新进展的审查.
- 对双特异性抗体 (抗CD19),抗体与药物合物 (抗CD22) 和针对CD38的疗法的疗效和应用的分析.
- 检查正在进行的临床试验及其对治疗策略的影响.
主要成果:
- 布利纳图莫马布 (抗CD19) 已被确立为复发性B细胞前体ALL,并且在高风险亚群中显示出希望.
- 伊诺图祖马布奥佐加米辛 (抗CD22) 在诱导复发ALL的缓解方面表现出高的疗效.
- 针对CD38的治疗方法,如达拉图巴,正在对T-ALL进行研究,对新诊断的ALL正在进行试验.
结论:
- 基于抗体的新型疗法有望显著改变儿科ALL治疗.
- 需要进一步的随机数据来充分评估达拉图姆巴等药物在T-ALL中的益处.
- 从成人ALL治疗创新中吸取的经验教训可以指导未来的儿科策略,旨在减少毒性和改善结果.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Hybridoma Technology
14.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.6K


